Aethlon Medical Acquires Strategic Cancer Therapy Patent
13th Nov 2006, 20:17 GMT
Aethlon Medical, a pioneer in developing therapeutic devices for infectious disease, announced that it's acquired world-wide rights to a patent submission entitled, De-repression of anticancer immunity through extracorporeal removal of microvesicular particles.
Aethlon Medical Acquires Strategic Cancer Therapy Patent related news:
- SpectraScience files new patent application — News-Medical News Feed
- Scientists Design A PSA-activated Protoxin That Kills Prostate Cancer: Phase I Clinical Trial Is Under Way — Health News from Medical News Today
- Long-Term Data Shows No Increase In Cancer Cases From Biologic Therapy — Health News from Medical News Today
- Shorter-course Radiation Treatment Safe For Breast Cancer — Health News from Medical News Today
- Adding Bevacizumab to First-Line Lung Cancer Therapy Shows Potential — Medscape Headlines
- Is Revascularization or Medical Therapy Best for Renal Artery Stenosis? — Medscape Nephrology Headlines
- Adding radiation therapy for treatment of advanced prostate cancer may offer benefit — EurekAlert! - Medicine and Health
- Other highlights in the November 15 JNCI — EurekAlert! - Biology
- WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions — Cardiology News from StratCenter.com
- SSRI Plus Cognitive Behavioral Therapy Effective for Pathological Gambling — Medscape Psychiatry Headlines
Latest news from Financial News News from StratCenter.com:
- TRADE NEWS: Agilent Technologies Introduces High-Speed, High-Volume USB Multifunction Data Acquisition Modules, Chassis
- Bio-Rad Closes Buy of Ciphergen Unit
- The LGL Group Reports Q3 Earnings
- Analogic CEO to retire
- Analogic CEO Plans to Retire
- Meade Instruments Contracts with Leading Asian Outsource Manufacturing Firm
- JMAR Receives Nasdaq Delisting Notice
- Analogic Corp Announces Mgmt Changes
- Bio-Rad Purchases Life Science Research Business From Ciphergen Biosystems
- Agilent to buy Switzerland's Acqiris